Ukwelashwa Komdlavuza Wesibindi e-China 2026: Izidakamizwa Nezindleko Zakamuva - Izibhedlela Eziseduze Nami 

Umdlavuza esibindini, ikakhulukazi i-hepatocellular carcinoma (HCC), isimila esiyingozi esivela kumangqamuzana esibindi esidinga ukungenelela okusheshayo, okuhlukahlukene. Ngo-2026, iChina yavela njengomholi womhlaba wonke ekwelashweni komdlavuza wesibindi, ihlinzeka ngenhlanganisela ye-immunotherapy esezingeni eliphezulu, amasu okuhlinza athuthukile njenge-robotic hepatectomy, kanye nezikhungo zokunakekela eziphelele eBeijing. Iziguli ezifuna ukwelashwa manje ziyakwazi ukufinyelela emithini emisha egunyazwe njengeLenvatinib ehlanganiswe ne-TACE kanye ne-PD-1 inhibitors inoveli, ethuthukisa kakhulu amazinga okusinda nokulawulwa kwezifo uma kuqhathaniswa neminyaka edlule.

Ukuqonda Umdlavuza Esibindini: Izinhlobo Nezinto Eziyingozi

Lapho kuxoxwa umdlavuza esibindini, kubalulekile ukuhlukanisa phakathi kwezinhlobo eziyisisekelo nesesibili. Umdlavuza wesibindi oyinhloko usuka esibindini ngokwaso, kanti i-Hepatocellular Carcinoma (HCC) ibalwa ngeningi lamacala. Umdlavuza wesibindi wesibili, noma umdlavuza we-metastatic, usakazekela esibindini usuka kwezinye izitho ezifana nekholoni noma ibele. Izinqubo zokwelashwa zihluka kakhulu ngokusekelwe kulo mehluko.

Ukuthuthukiswa komdlavuza wesibindi oyinhloko kuvame ukuhlotshaniswa nezimo zesibindi ezingapheli. Amaqembu asengozini enkulu ahlanganisa abantu abangaphezu kweminyaka engama-40 ubudala, ikakhulukazi amadoda, nabesifazane abangaphezu kweminyaka engama-50 abanomlando wokutheleleka nge-Hepatitis B noma C. Ukuphuza utshwala isikhathi eside, isifo sikashukela, kanye nomlando womndeni womdlavuza wesibindi nakho kuphakamisa amazinga engozi kakhulu.

• I-Hepatitis Virus: Ukutheleleka okungamahlalakhona ngeHepatitis B (HBV) noma iHepatitis C (HCV) kuyimbangela ehamba phambili emhlabeni wonke naseShayina.
• I-Cirrhosis: Ukulimala kwezicubu zesibindi kunoma yisiphi isizathu kwandisa amathuba okuba noshintsho olubi.
• Izinto Zendlela Yokuphila: Ukusetshenziswa kotshwala okunzima kanye nokuphazamiseka kwe-metabolic okufana nesifo sesibindi esinamafutha angenaso utshwala (NAFLD) kuyanda abanegalelo.
• Ubuthi Bemvelo: Ukuchayeka kuma-aflatoxin atholakala kuzinhlamvu ezikhuntile kungaba nomthelela ekuguqukeni kofuzo kumaseli esibindi.

Ukutholwa kusenesikhathi kuseyisici esibaluleke kakhulu semiphumela eyimpumelelo. Iziqondiso zezokwelapha zitusa ukuthi abantu abasengozini enkulu bahlolwe njalo ngemva kwezinyanga eziyisithupha. Lokhu ngokuvamile kuhilela izithombe ze-ultrasound nokuhlolwa kwegazi kwamazinga e-alpha-fetoprotein (AFP). Ukutholwa kwesigaba sangaphambi kwesikhathi kuvumela izinketho zokwelapha ezifana nokuhlinzwa kabusha noma ukufakelwa isibindi, kuyilapho ukuxilongwa kwesigaba sekwephuzile kuvame ukukhawulela ukwelashwa ekunakekelweni kwenhliziyo noma ukwelashwa okuhlelekile.

Izibhedlela Eziphezulu Zokwelashwa Komdlavuza Wesibindi e-Beijing 2026

I-Beijing isebenza njengendawo yezokwelapha e-China, isingathe izikhungo ezimbalwa ezisezingeni lomhlaba ezisebenza nge-hepatobiliary oncology. Okweziguli zamazwe ngamazwe nezasekhaya ezifuna ukunakekelwa okungcono kakhulu umdlavuza esibindini, izibhedlela ezintathu zihlala zisezingeni eliphezulu ngenxa yamakhono azo abanzi, umphumela wocwaningo, nobungcweti bokuhlinza.

Isibhedlela i-Peking Union Medical College (PUMCH)

I-Chinese Academy of Medical Sciences Isibhedlela i-Peking Union Medical College sithathwa kabanzi njengesikhungo sikaNdunankulu samacala ayinkimbinkimbi. Umnyango Wawo Wokuhlinza Isibindi waziwa ngokuphatha amacala anzima futhi ayinkimbinkimbi ezinye izikhungo ezingase ziwabone engasebenzi. Lesi sibhedlela sihamba phambili kuzwelonke emithini yokunakekelwa kwababucayi, okubalulekile ekululameni kwangemva kokuhlinzwa ekuhlinzweni kwesibindi.

I-PUMCH inikeza indlela edidiyelwe yethimba le-multidisciplinary (MDT). Lokhu kusho ukuthi odokotela abahlinzayo, izazi ze-oncologists, izazi nge-radioologists, kanye nezazi zezifo babambisana kuzo zonke izimo ukuze benze uhlelo lokwelapha lomuntu siqu. Lesi sikhungo sinemibhede evulekile engaphezu kuka-2,000 futhi sinesikhundla njengesikhungo esikhethekile emikhakheni eyisikhombisa yesifundazwe. Ukuzibophezela kwabo emfundweni yesiguli kubonakala ngemizamo ebanzi yokwandisa isayensi yomdlavuza.

Isibhedlela Esijwayelekile saseShayina se-PLA (301 Hospital)

Isibhedlela Esijwayelekile saseShayina i-PLA, ikakhulukazi uMnyango Wokuhlinza I-Hepatobiliary and Pancreatic Surgery, siwumthombo onamandla ekusungulweni kokuhlinza. Ikleliswe endaweni yesithathu kuzwelonke ekusebenzeni okuphelele kwesibhedlela, ingumholi ekufakweni kwesibindi nokuhlinza okuyinkimbinkimbi. Lo mnyango uholwa ochwepheshe abavelele asebeneminyaka engamashumi eminyaka ekwelapheni izimila eziyingozi ohlelweni lwe-hepatobiliary.

Lesi sikhungo siyisikhungo esikhethiwe sokuhlolwa kwezidakamizwa (GCP), esivumela iziguli ukufinyelela ekuhlolweni komtholampilo kweSigaba II kanye nesesi-III ukuthola imithi emisha. Isungule ukubambisana kwamazwe ngamazwe ne-University of Pittsburgh Medical Center (UPMC), yenza kube lula ukushintshana kwamasu okuhlinza athuthukile kanye nezinqubo zokwelapha. Isibhedlela siphinde sibe nesikhungo socwaningo lwezokwelapha lwedijithali esisebenzisa amasistimu okuxilonga asiza nge-AI ukuze kuthuthukiswe ukunemba.

Peking University People's Hospital

I-Peking University People's Hospital ihlinzeka ngokunakekelwa okukhethekile ngoMnyango wayo Wokuhlinza I-Hepatobiliary. Ibekwe endaweni ephakeme kakhulu esifundeni saseNyakatho neChina, ihlanganisa ubuhle bokuhlinza bendabuko nokwelashwa kwesistimu yesimanje. Lesi sibhedlela siyisikhungo semfundo ephakeme i-Grade A esinegama lomshwalense wezempilo, okwenza sifinyeleleke ezigulini eziningi.

Njengozakwabo, igcizelela imodeli ye-MDT futhi inikeza iminyango ekhethekile kuhlanganise nokuhlinzwa okuvamile, i-oncology ebanzi, i-oncology yendabuko yamaShayina, kanye ne-radiotherapy. Lokhu bubanzi bezinsizakalo kuqinisekisa ukuthi kungakhathaliseki ukuthi isiguli sidinga ukukhishwa kancane kancane, ukwelashwa ngamakhemikhali okunamandla, noma ukunakekelwa kwe-TCM okusekelayo, zonke izinsizakalo zitholakala ngaphansi kophahla olulodwa.

Izidakamizwa kanye Nokwelashwa Okuphumelelayo Kugunyazwe ngo-2026

Indawo yokwelapha umdlavuza esibindini ishintshe kakhulu ngo-2026 ngokugunyazwa kwezindlela zokwelapha ezimbalwa ezihamba phambili. Okugxilwe kukho kusuke ekwelashweni komenzeli oyedwa kuya ezinhlotsheni zemithi ezihlanganisa izindlela eziningi ngesikhathi esisodwa, okuholela emazingeni aphezulu okuphendula kanye nokuphila isikhathi eside.

I-Lenvatinib Ihlanganiswe ne-TACE kanye ne-Immunotherapy

Ingqophamlando enkulu yenzeka ngoJulayi 2025, ngokusetshenziswa ngokugcwele ngo-2026, mayelana nokugunyazwa kwe-Lenvatinib (Lenvima®). Le oral multi-target tyrosine kinase inhibitor (TKI) enamandla kakhulu ithole ukugunyazwa kwenkomba entsha: ukuhlanganisa i-Lenvatinib ne-Pembrolizumab kanye ne-Transarterial Chemoembolization (TACE). Lolu hlobo lwemithi emithathu ye-“TACE + Targeted + Immune” ingeyokuqala ngqa emhlabeni wonke ukuthi igunyazwe ngokusemthethweni i-HCC engeyona eye-metastatic engalungiseki.

Idatha yomtholampilo evela ocwaningweni lweSigaba III se-LEAP-012 ibonise ukusebenza kahle okumangalisayo. Iqembu lokwelapha okuhlanganisiwe lizuze isilinganiso sokusinda sezinyanga ezingama-24 (i-OS) esingu-75%, ladlula iqembu elilawulayo. Ngaphezu kwalokho, i-median progression-free survival (PFS) inwetshelwe ezinyangeni ze-14.6, ukuthuthukiswa okuphawulekayo phakathi nezinyanga ze-10.0 ezibonwa emaqenjini okunakekela ajwayelekile. Lolu hlobo lwemithi manje seluyinketho evamile ezigulini izimila zazo ezingakwazi ukususwa ngokuhlinzwa kodwa ezingakasakazeki ezithweni ezikude.

I-Finotonlimab ne-Bevacizumab Combination

Enye inqubekelaphambili ebalulekile ukugunyazwa kwe-Finotonlimab (SCT-I10A), i-anti-PD-1 monoclonal antibody eyakhiwe ekhaya. Ekuqaleni kuka-2025, yagunyazwa ukuthi isetshenziswe ngokuhambisana ne-Bevacizumab (SCT510) ezigulini ezine-HCC engahlanjululwa noma ene-metastatic ezingakatholi ukwelashwa okuhleliwe kwangaphambili. Lokhu kwelashwa okukabili kuqondise kokubili indawo yokuhlola ye-PD-1 kanye ne-vascular endothelial growth factor (VEGF).

Idatha yomhlaba wangempela nezivivinyo zomtholampilo zibonisa Izinga Lokusabela Kwenjongo (ORR) lama-33% ale nhlanganisela, ephakeme kakhulu kuno-4% obonwe emaqenjini okulawula. Iziguli zithole ukuncipha kwe-50% engcupheni yokuqhubeka kwesifo, nge-PFS emaphakathi yezinyanga ze-7.1. Okubaluleke kakhulu, ukusinda okuphelele okuphakathi kwafinyelela ezinyangeni ze-22.1, kunciphisa ingozi yokufa ngama-40% uma kuqhathaniswa namazinga angaphambilini. Lokhu kunikeza ithemba elisha ezigulini ezinesifo esisezingeni eliphezulu.

I-"O+Y" Dual Immunotherapy Regimen

Inhlanganisela ye-Nivolumab (Opdivo®) kanye ne-Ipilimumab (Yervoy®), eyaziwa ngokuthi uhlobo lwe-“O+Y”, iqinise isikhundla sayo njengokwelashwa komugqa wokuqala kwe-HCC engalungiseki. Igunyazwe e-China ekuqaleni kuka-2025, le ndlela yokuhlola i-immune checkpoint inhibitor ivimba yomibili imizila ye-PD-1 ne-CTLA-4. Isebenza kakhulu ezigulini okungenzeka zingayibekezeleli imiphumela engemihle ye-TKI noma ezinezimpawu ezithile ze-tumor biomarker.

Lolu hlobo lumelela ukushintshela ezinkethweni ezingenawo i-chemotherapy zomdlavuza wesibindi othuthukile. Ngokukhulula amasosha omzimba ukuze ahlasele amangqamuzana omdlavuza avela ezinhlangothini ezimbili ezihlukene, angakwazi ukuletha izimpendulo ezihlala isikhathi eside kusethi yeziguli, ezinye zazo ezithola ukuxolelwa isikhathi eside. Ukutholakala kwalokhu kwelashwa ezibhedlela ezinkulu zase-Beijing kuqinisekisa ukuthi iziguli zaseShayina ziyakwazi ukuthola imishanguzo yokwelapha esezingeni elifanayo etholakala e-US naseYurophu.

Izindlela Zokwelapha Eziphelele Ziyatholakala e-China

Ukwelapha umdlavuza esibindini ngo-2026 akuvamile ukuba kube indlela yokulinganisa konke. Izikhungo zezokwelapha zaseShayina zisebenzisa isu le-multimodal, elihlanganisa ukungenelela esigabeni somdlavuza, umsebenzi wesibindi esisele, kanye nempilo yonke yesiguli. Izinga lamanje lokunakekelwa limelela imodeli yeThimba Leningi (MDT).

Ukuhlinzwa Ukuhlinzwa kanye Nokufakelwa Kwesibindi

Ukuhlinzwa kusewukuphela kwendlela yokwelapha umdlavuza wesibindi osanda kuqala. Ukuhlinzwa kabusha kuhilela ukususa isimila kanye nomkhawulo wezicubu ezinempilo. Intuthuko ekuhlinzeni i-robotic kanye nezindlela ze-laparoscopic ziye zanciphisa izikhathi zokululama kanye nezinkinga. Ezigulini ezinomdlavuza wesigaba sokuqala esihambisana ne-cirrhosis enzima, ukufakelwa kwesibindi kuyindlela ekhethwayo, njengoba kususa kokubili isimila kanye nesibindi esigulayo.

Ngo-2026, imibandela yokufakelwa kabusha iye yathuthukiswa ukuze ifake amaphrothokholi aphansi. Iziguli ekuqaleni ngaphandle kwenqubo yokufakelwa zingase zithole ukwelashwa kwendawo ukuze zishwabe izimila, zizenze zifanelekele ukufakelwa kabusha. Izikhungo ezinkulu e-Beijing zenza amakhulukhulu alezi zinqubo eziyinkimbinkimbi minyaka yonke ngamazinga aphezulu empumelelo.

Imithi Yokwelapha Yendawo

Kumathumba amancane (ngokuvamile angaphansi kuka-3 cm) angafaneleki ukuhlinzwa, ukukhishwa kwendawo kungenye indlela esebenza kahle kakhulu. Lokhu kubandakanya i-Radiofrequency Ablation (RFA) kanye ne-Microwave Ablation (MWA). Lezi zinqubo ezihlasela kancane zisebenzisa ukushisa ukuze zibhubhise amangqamuzana omdlavuza ngokuqondile. Imvamisa zenziwa nge-percutaneously ngaphansi kokuqondiswa kwesithombe, ezidinga ukuhlala isikhashana esibhedlela.

I-Ablation iya ngokuya isetshenziswa ngokuhambisana nezinye izindlela zokwelapha. Isibonelo, ingase isetshenziselwe ukwelapha isifo esiyinsalela ngemva kwe-TACE noma ukulawula ukuphindelela ezigulini ezike zahlinzwa ngaphambilini. Ukunemba kwezithombe zesimanje kuvumela odokotela ukuthi baqonde izimila kuyilapho besindisa i-parenchyma yesibindi enempilo.

I-Transarterial Chemoembolization (TACE)

I-TACE isalokhu iyindinganiso yokunakekelwa komdlavuza wesibindi wesigaba esimaphakathi. Le nqubo ihilela ukujova izidakamizwa ze-chemotherapy ngqo emithanjeni edla isimila, kulandelwe ama-embolic agents ukuze kuvinjwe ukugeleza kwegazi. Lokhu "kulamba" isimila somoya-mpilo kanye nezakhamzimba ngenkathi iletha izidakamizwa eziningi endaweni.

Ukuvela kwe-TACE ngo-2026 kufaka phakathi ukuhlanganiswa kwayo nemithi yokwelapha ehlelekile. Njengoba kuphawuliwe ngokugunyazwa kwe-Lenvatinib, i-TACE ayiseyona i-silo ezimele kodwa iyingxenye yesu elibanzi lesistimu. Ubuhlalu obukhipha izidakamizwa kanye nezinto ezintsha ze-embolic zenze ngcono ukusebenza kahle kanye nephrofayili yokuphepha yale nqubo, kunciphisa izimpawu ze-post-embolization syndrome.

I-Systemic Therapy kanye Nemisebe

Ngezifo ezisezingeni eliphezulu, ukwelashwa kwe-systemic kuyisisekelo sokwelashwa. Lokhu kuhlanganisa ukwelashwa okuhlosiwe (TKIs), i-immunotherapy (i-checkpoint inhibitors), kanye nokwelashwa ngamakhemikhali ngezikhathi ezithile. I-arsenal yezidakamizwa ikhule kakhulu, ivumela imigqa yokwelapha elandelanayo uma umugqa wokuqala wehluleka.

Ukwelapha ngemisebe, okuhlanganisa i-Stereotactic Body Radiation Therapy (SBRT) kanye ne-Proton Beam Therapy, kudlala indima ebaluleke kakhulu. Lobu buchwepheshe buletha imithamo ephezulu yemisebe enembayo ngokwedlulele, enciphisa umonakalo esicutshini sesibindi esinempilo. Awusizo ikakhulukazi kumathumba aseduze nemithambo yegazi emikhulu noma ezigulini ezine-portal vein thrombosis.

Ukuhlaziywa Kwezindleko: Izindleko Zokwelashwa ngo-2026

Ukuqonda imithelela yezezimali kuyingxenye ebalulekile yohambo lwesiguli. Izindleko zokwelashwa umdlavuza esibindini eShayina kuyehluka kakhulu kuye ngesigaba sesifo, indlela yokwelashwa ekhethiwe, kanye nesikhathi sokunakekelwa. Nakuba izindleko zingaba nkulu, ukufakwa kwemithi eminingi emisha ezinhlelweni zomshwalense wezokwelapha kazwelonke kuthuthukise ukufinyeleleka.

Izindleko Zokuhlinza

Ezigulini ezisesigabeni sangaphambi kwesikhathi ezihlinzwa kabusha, izindleko eziphelele ngokuvamile zisukela ku-50,000 kuya ku-150,000 RMB. Lesi silinganiso sihlanganisa ukuhlolwa kwangaphambi kokuhlinzwa, inqubo yokuhlinzwa ngokwayo, izinzwa, nokulaliswa esibhedlela. Izimo eziyinkimbinkimbi ezidinga ukuhlala isikhathi eside e-ICU noma ukuphathwa kwezinkinga kungase kudlule leli banga.

Ukufakelwa kwesibindi kuyindlela yokuhlinzwa ebiza kakhulu. Izindleko eziyisisekelo zokuhlinzwa zidlula i-200,000 RMB. Kodwa-ke, lapho kufakwa ekwelashweni kwe-immunosuppressive yesikhathi eside nokunakekelwa kokulandelela, inani lezindleko zokuphila lingedlula i-800,000 RMB. Ngaphandle kokutshalwa kwezimali okuphezulu kokuqala, ukufakelwa kabusha kunikeza ithuba elingcono kakhulu lokusinda isikhathi eside kumakhandidethi afanelekayo.

Izindleko Zokungenela Nezokwelashwa Kwendawo

Izinqubo zokungenelela ezifana ne-TACE ngokuvamile zithengeka kakhulu ngeseshini ngayinye, zibiza phakathi kuka-10,000 no-30,000 RMB. Kodwa-ke, umdlavuza wesibindi uvame ukudinga izikhathi eziningi ngokuhamba kwesikhathi, okuqoqa izindleko. Ezigulini ezinezinkinga ze-cirrhosis ezifana ne-ascites noma ukopha kwamathumbu, ukulaliswa esibhedlela ukuze uthole ukunakekelwa okusekelayo kungase kube kusuka ku-10,000 kuya ku-50,000 RMB yokungeniswa ngakunye.

Imithi yokwelapha ingena ngaphakathi kwezindleko ezifanayo zebakaki ku-TACE, ngokuvamile kusukela ku-15,000 kuya ku-30,000 RMB ngeseshini ngayinye kuye ngobuchwepheshe obusetshenziswa (isb., i-microwave vs. radiofrequency) kanye nenani lezimila elashwayo.

Ukwelashwa Okuhlelekile Nezindleko Zomuthi

Izindleko zokwelashwa kwe-systemic beziwumthwalo ngokomlando, kodwa isimo sezwe siyashintsha. Iziguli esezifike kamuva zisebenzisa izidakamizwa ezihlosiwe njenge-Sorafenib noma ama-immunotherapies amasha zingase zibhekane nezindleko zonyaka ezisukela ku-200,000 kuya ku-500,000 RMB uma zikhokha ngaphandle kwephakethe. Amanye ama-ejenti aqondisiwe anoveli angabiza ngaphezulu kwama-RMB angama-30,000 ngenyanga.

Kodwa-ke, eminingi yale mithi, okuhlanganisa i-Lenvatinib kanye ne-PD-1 inhibitor ehlukahlukene, ifakwe ohlwini lwezidakamizwa lwase-China Lokubuyisela Imali (NRDL). Lokhu kufakwa kunciphisa kakhulu izindleko eziphuma ephaketheni zeziguli ezifakwe umshwalense, ngezinye izikhathi kwehlisa izindleko zenyanga zibe izinkulungwane ezimbalwa ze-RMB. Izindleko zokwelapha ngemisebe ziyahlukahluka ngobuchwepheshe, ngemisebe evamile ebiza u-20,000 kuya ku-50,000 RMB, kuyilapho ukwelashwa kwe-proton okuthuthukisiwe kungadlula i-100,000 RMB isifundo ngasinye.

I-ICU kanye Nezindleko Zokunakekelwa Okubalulekile

Ezigulini ezinesifo sesibindi sokuphela noma ukwehluleka kwesibindi, ukunakekelwa okujulile ngokuvamile kuyadingeka. Izindleko zansuku zonke e-ICU zingasukela ku-3,000 kuya ku-5,000 RMB. Ukwelashwa okukhethekile okufana nokushintshisana kwe-plasma noma amasistimu asekela isibindi sokwenziwa kwengeza kumthethosivivinywa, ngeseshini eyodwa ebiza ngaphezu kuka-10,000 RMB. Lezi zindleko zigqamisa ukubaluleka kokutholwa kusenesikhathi nokungenelela ukuze kuvinjelwe ukuqhubekela phambili ezigabeni ezibucayi.

Ukuhlaziywa Okuqhathanisayo Kwamasu Okwelapha

Ukukhetha indlela yokwelapha efanele kuncike ekuhloleni ngokucophelela izinzuzo nemikhawulo. Ukuqhathanisa okulandelayo kuveza amasu ayinhloko atholakalayo okuphatha umdlavuza esibindini endaweni yamanje yezokwelapha.

Indlela ngayinye inezinzuzo ezihlukile. Ukuhlinzwa kunikeza ithuba eliphakeme kakhulu lokwelapha kodwa kunezingozi zokuhlinzwa. Ukukhipha isisu kuphephile futhi kusebenza kahle ezilonda ezincane kodwa kuncane kakhulu kumathumba amakhulu. I-TACE ilawula ukukhula kwesimila ngempumelelo ezigabeni ezimaphakathi kodwa ayivamisile ukwelapha iyodwa. Izindlela zokwelapha ezihleliwe ziye zashintsha ukunakekelwa kwezifo ezithuthukile, zashintsha ukutholakala okubulalayo kwaba yisimo esingelapheki esilawulekayo kwabaningi.

Ukubi nakho kufanele kukalwe. Ukuhlinzwa nokufakelwa kabusha kudinga isikhathi esibalulekile sokululama futhi kunezingozi zokopha noma ukutheleleka. Ukukhipha isisu kungase kungawaqedi ngokuphelele amathumba amakhulu, okuholela ekuphindekeni kwendawo. I-TACE ingabangela i-post-embolization syndrome (umkhuhlane, ubuhlungu, isicanucanu). Imithi yokwelapha ehlelekile ingadala izehlakalo ezimbi ezihlobene nokuzivikela komzimba noma umfutho wegazi ophakeme kanye nokusabela kwesikhumba sonyawo lwesandla kusuka kuma-TKI.

Isinyathelo ngesinyathelo Umhlahlandlela Wokufuna Ukwelashwa e-Beijing

Okweziguli ezihlela ukufuna ukwelashwa umdlavuza esibindini e-Beijing, ukuzulazula ohlelweni lokunakekelwa kwezempilo kubalulekile. Izinyathelo ezilandelayo zichaza inqubo evamile kusukela ekubonisaneni kokuqala kuya ekuqalisweni kokwelashwa.

• Isinyathelo 1: Qoqa Amarekhodi Ezokwelapha: Hlanganisa yonke imibhalo yezokwelapha ekhona, okuhlanganisa ukuskena kwezithombe (CT, MRI), imibiko ye-pathology, imiphumela yokuhlolwa kwegazi (ikakhulukazi i-AFP nokusebenza kwesibindi), kanye nesifinyezo sokwelashwa kwangaphambilini. Amakhophi edijithali kudrayivu ye-USB noma isixhumanisi samafu anconywa kakhulu.
• Isinyathelo sesi-2: Khetha Isibhedlela Nomnyango: Khetha isibhedlela esisezingeni eliphezulu njenge-PUMCH, i-PLA General Hospital, noma i-Peking University People's Hospital. Khomba umnyango othize, ngokuvamile Ukuhlinzwa Kwe-Hepatobiliary, I-Oncology, noma I-Interventional Radiology, kuye ngesiteji esisolwayo.
• Isinyathelo sesi-3: Ukubhaliswa Kwe-aphoyintimenti: Bhalisela isikhathi sokubonana ngohlelo lokusebenza olusemthethweni lwesibhedlela, iwebhusayithi, noma ngesevisi yezokwelashwa. Ezigulini zakwamanye amazwe, izibhedlela eziningi zinikezele ngeminyango yezokwelapha yamazwe ngamazwe esiza ngezithiyo zolimi kanye nelogistics.
• Isinyathelo sesi-4: Ukubonisana Kwasekuqaleni kanye Nokubuyekezwa kwe-MDT: Yiya ekubonisaneni lapho ochwepheshe bazobuyekeza udaba lwakho. Ezibhedlela eziphezulu, amacala ayinkimbinkimbi avame ukuxoxwa ngawo emhlanganweni we-MDT ohilela odokotela abahlinzayo, odokotela be-oncologists, nama-radiologists ukuze bakhe uhlelo lokwelapha oluhlangene.
• Isinyathelo 5: Ukuhlola Okwengeziwe: Zilungiselele ukuhlolwa okwengeziwe ukuze ubuyekeze isimo sakho. Lokhu kungase kuhlanganise i-MRI ethuthukisiwe, i-PET-CT, noma ukuhlolwa kofuzo ukuze kunqunywe ukufaneleka kwemithi ethile eqondiwe noma izivivinyo zomtholampilo.
• Isinyathelo sesi-6: Ukuqaliswa Kokwelashwa: Uma uhlelo sekuvunyelwene ngalo, hlela inqubo noma uqale imithi. Ngokuhlinzwa, kungase kube nesikhathi sokulinda sokutholakala kombhede. Ukuze uthole ukwelashwa kwezidakamizwa, ukwelashwa kungase kuqale ngokushesha.
• Isinyathelo sesi-7: Ukulandelela Nokuqapha: Namathela ngokuqinile esimisweni sokulandelela. Ukuqapha njalo kubalulekile ukuhlola impendulo yokwelashwa nokulawula imiphumela engemihle. Izibhedlela eziningi zinikeza izinkundla eziku-inthanethi zokubonisana okulandelayo.

Iqhaza lamaQembu Emisebenzi Ehlukahlukene (MDT) Ekunakekelweni Kwesimanje

Ubunkimbinkimbi be umdlavuza esibindini idinga indlela yokusebenzisana. Imodeli ye-MDT manje iyindinganiso yegolide ezibhedlela zaseShayina ezihamba phambili. Esikhundleni sokubona udokotela oyedwa, icala lesiguli lihlolwa ithimba lochwepheshe abavela kumakhono ahlukene. Lokhu kuqinisekisa ukuthi zonke izindlela zokwelapha ziyacatshangelwa ngaphambi kokuba kuthathwe isinqumo.

I-MDT ngokuvamile ihlanganisa odokotela abahlinza i-hepatobiliary, i-oncologists yezokwelapha, ama-radiologist angenele, i-radiation oncologists, izazi zezifo, nabahlengikazi abakhethekile. Isibonelo, udokotela ohlinzayo angase akhuthaze ukukhishwa kabusha, kuyilapho i-oncologist iphakamisa ukwehlisa isimila ngokwelashwa kwesistimu kuqala ukuze kuthuthukiswe imiphumela. Ukuvumelana okufinyelelwe yi-MDT kunikeza isiguli isu lokwelapha elinengqondo ngokwesayensi nelomuntu siqu.

Ngaphezu kwalokho, ama-MDT asiza ukufinyelela ezinhlolweni zomtholampilo. Njengoba izibhedlela ezifana ne-PLA General Hospital esebenza njengamayunithi e-GCP, iziguli okuxoxwe ngazo emihlanganweni ye-MDT zingahlonzwa ngokushesha ukuze zibhaliswe ezivivinyweni ezihlola imithi emisha njenge-Finotonlimab noma inhlanganisela yemithi yenoveli. Lokhu kuhlanganiswa kocwaningo nokusebenza komtholampilo kusheshisa ukutholakala kwezindlela zokwelapha ezintsha kulabo abazidinga kakhulu.

I-future Outlook kanye ne-Emerging Technologies

Uma sibheka ngale kuka-2026, ikusasa lokwelapha umdlavuza esibindini ibonakala ithembisa. Ucwaningo lugxile kakhulu ekwelashweni okunembayo, lapho ukwelashwa kwenziwa ngendlela efanele ngokusekelwe ekwakhekeni kofuzo lwesimila somuntu. Ama-Liquid biopsies, athola i-DNA yesimila egazini, aya evame kakhulu ukuze atholakale kusenesikhathi kanye nokuqapha impendulo yokwelashwa ngaphandle kwezinqubo ezihlaselayo.

I-Artificial Intelligence (AI) nayo idlala indima yokuguqula. Izibhedlela eBeijing zisebenzisa izinhlelo zokuxilonga ezisizwa yi-AI ukuze zihlaziye izikena zezithombe ngokunemba okukhulu kunamehlo omuntu ewodwa. Lezi zinhlelo zingakwazi ukubona izimpawu ezicashile zokuvela kabusha kwesimila noma zibikezele ukuthi isimila sizosabela kanjani emithini ethile, zisize odokotela ekwenzeni izinqumo ezinolwazi.

Ukwengeza, ukuthuthukiswa kwe-immunotherapies yesizukulwane esilandelayo kuyaqhubeka. Abacwaningi bahlola amasosha omzimba we-bispecific kanye nokwelashwa kwamaseli e-CAR-T aklanyelwe ngokukhethekile izimila eziqinile njenge-HCC. Nakuba kusesezivivinyweni zomtholampilo, lobu buchwepheshe bunamandla okuthuthukisa amazinga okusinda kanye nekhwalithi yokuphila yeziguli ezinesifo esithuthukile.

Isiphetho

Ukuzulazula ekuxilongweni kwe umdlavuza esibindini kuyinselele, kodwa intuthuko yezokwelapha efinyelelwe ngo-2026 inikeza ithemba elingakaze libonwe. I-China, ikakhulukazi i-Beijing, ihamba phambili kule nqubekelaphambili, ihlinzeka ngokufinyelela ezibhedlela ezisezingeni lomhlaba, amathimba ochwepheshe abahlinzayo, kanye nemithi yakamuva eyimpumelelo. Kusukela emandleni okwelapha okuhlinzwa nokufakelwa kabusha kuya ezinzuzweni ezinwetshwayo zokuphila zenhlanganisela entsha ye-immunotherapy efana ne-Lenvatinib plus TACE kanye ne-Finotonlimab, i-arsenal yokwelapha inamandla kakhulu kunangaphambili.

Iziguli zikhuthazwa ukuthi zifune ukunakekelwa ezikhungweni ezikhethekile ezisebenzisa indlela ye-Multidisciplinary Team (MDT) ukuze kuqinisekiswe ukwelashwa okuphelele nokuqondene nomuntu. Nakuba izindleko zingahluka, ukufakwa kwemithi ebalulekile ezinhlelweni zomshwalense kazwelonke kanye nokutholakala kwezinketho zokwelashwa ezihlukahlukene kwenza ukunakekelwa okuphumelelayo kufinyeleleke kakhudlwana. Ukutholwa kusenesikhathi kuseyisikhali esinamandla kakhulu; ukuhlolwa okuvamile kwabantu abasengozini enkulu kungaholela ekuxilongweni kwesifo esigabeni lapho ukwelashwa kokwelapha kungenzeka khona. Ngokuqhubekayo emisha kanye nokugxila okugxile esigulini, umbono weziguli ezinomdlavuza wesibindi uyaqhubeka uthuthuka unyaka nonyaka.